Exhibit 99.1 ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Expect to report multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential initiation of multiple registrational trials SOUT ...

Exhibit 99.1 News Release Allison Transmission Announces Fourth Quarter and Full Year 2025 Results INDIANAPOLIS, February 23, 2026 – Allison Transmission Holdings Inc. (NYSE: ALSN) today reported full year 2025 net sales of $3 billion with Adjusted EBITDA margin of 37.5 percent and net cash provided by operating activities of $836 million. David S. Graziosi, Chair, President and Chief Executive Officer of Allison commented, "Although 2025 presented meaningful macroeconomic challenges, we remained discipline ...

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36866 Summit Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 37-1979717 (State or Other Jurisdiction of Incorporation or Organization) _____________________________ FORM 10-K _____________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ...

Exhibit 99.1 MEDIAALPHA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Fourth Quarter Revenue of $291 million and Record Transaction Value of $613 million; Record Transaction Value of $552 million in Property & Casualty Insurance Vertical Record Full-Year 2025 Revenue of $1.1 billion and Transaction Value of $2.2 billion Record Full-Year 2025 Net Income of $26.8 million and Adjusted EBITDA of $113.7 million (1) Board of Directors Doubles Share Repurchase Authorization to $100 million Los Ange ...

ACV Announces Fourth Quarter and Full-Year 2025 Results 15% Revenue Growth and Adjusted EBITDA Exceeding High-End of Guidance Full-Year 2025 Highlights First Quarter and Full-Year 2026 Guidance BUFFALO, February 23, 2026 — ACV (NYSE: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, today reported results for its fourth quarter and full-year ended December 31, 2025. "We are very pleased with our fourth quarter results, with revenue at the high-end ...

Exhibit 99.1 Keysight Technologies Reports First Quarter 2026 Results Achieved record revenue with double-digit growth across business segments SANTA ROSA, Calif., February 23, 2026 - Keysight Technologies, Inc. (NYSE: KEYS) today reported financial results for the first fiscal quarter ended January 31, 2026. "Keysight had a strong start to the fiscal year with outstanding results that exceeded our expectations," said Satish Dhanasekaran, Keysight's President and CEO. "The investments we have made over the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 27, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to_______ Commission file number 1-35166 Fortune Brands Innovations, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorpora ...

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements Generated full-year 2025 net product sales of XDEMVY of $451.4 million, an increase of more than 150% year-over-year ® Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference ca ...

Exhibit 99.1 Backblaze Announces Fourth Quarter and Full Year 2025 Financial Results 24% Revenue Growth in B2 Cloud Storage, 12% Revenue Growth Overall in Q4 2025 San Mateo, CA (February 23, 2026)—Backblaze, Inc. (Nasdaq: BLZE), the high-performance cloud storage platform for the AI era, today announced results for its fourth quarter ended December 31, 2025. "In Q4, we closed our first eight-figure TCV neocloud agreement," said Gleb Budman, co-founder and CEO of Backblaze. "This marks yet another neocloud w ...

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance , with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million 1 SAN FRANCISCO, February 23, 2026 – Hims ...